FDA panel supports Perjeta for early-stage breast cancer

FDA panel supports Perjeta for early-stage breast cancer

WASHINGTONA biotech drug from Roche moved one step closer Thursday to becoming the first medicine approved to treat breast cancer before surgery. The Food and Drug Administration's panel of cancer experts voted 13-0, with one abstention, that the 

2
Like
Save

Comments

Write a comment

*